• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.

作者信息

Zhu You-Cai, Wang Wen-Xian, Li Xing-Liang, Xu Chun-Wei, Chen Gang, Zhuang Wu, Lv Tangfeng, Song Yong

机构信息

Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, People's Republic of China.

Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2019 Aug;14(8):e181-e183. doi: 10.1016/j.jtho.2019.03.031.

DOI:10.1016/j.jtho.2019.03.031
PMID:31345345
Abstract
摘要

相似文献

1
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.通过下一代测序在肺腺癌中鉴定一种新型的对埃克替尼敏感的EGFR-SEPTIN14融合变体
J Thorac Oncol. 2019 Aug;14(8):e181-e183. doi: 10.1016/j.jtho.2019.03.031.
2
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.一名携带EGFR L858R和Q787k突变的肺腺癌患者对埃克替尼的原发性耐药
Lung Cancer. 2019 Oct;136:153-155. doi: 10.1016/j.lungcan.2019.07.030. Epub 2019 Jul 31.
3
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.厄洛替尼联合化疗对比单纯化疗一线治疗表皮生长因子受体敏感突变晚期肺腺癌的随机对照研究
Lung Cancer. 2019 Jul;133:23-31. doi: 10.1016/j.lungcan.2019.05.008. Epub 2019 May 7.
4
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.金雀异黄素，一种特异性 CK2 抑制剂，能够降低人肺腺癌细胞株对伊可替尼的耐药性。
Int J Mol Med. 2019 Aug;44(2):437-446. doi: 10.3892/ijmm.2019.4220. Epub 2019 May 30.
5
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.埃克替尼与传统化疗作为表皮生长因子受体敏感突变的晚期肺腺癌患者预防脑转移一线治疗的疗效比较
J Cancer Res Ther. 2016 Jul-Sep;12(3):1127-1131. doi: 10.4103/0973-1482.194599.
6
Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.埃克替尼对不同表皮生长因子受体（EGFR）表型的晚期非小细胞肺癌的影响。
Cell Biochem Biophys. 2014 Sep;70(1):553-8. doi: 10.1007/s12013-014-9955-y.
7
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.埃克替尼与传统化疗作为表皮生长因子受体敏感突变的晚期肺腺癌患者预防脑转移一线治疗的疗效比较
J Cancer Res Ther. 2014 Nov;10 Suppl:C155-9. doi: 10.4103/0973-1482.145851.
8
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].[CK2抑制剂醌茜素增强埃克替尼对表皮生长因子受体酪氨酸激酶抑制剂耐药细胞系的抗增殖作用及其潜在机制]
Zhonghua Zhong Liu Za Zhi. 2016 Feb;38(2):100-4. doi: 10.3760/cma.j.issn.0253-3766.2016.02.005.
9
Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.埃克替尼在晚期非小细胞肺癌患者中的临床药代动力学、安全性及初步疗效评价
Lung Cancer. 2015 Sep;89(3):262-7. doi: 10.1016/j.lungcan.2015.05.024. Epub 2015 Jun 6.
10
Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.埃克替尼治疗肺鳞状细胞癌的疗效：来自单机构的真实世界经验。
Asia Pac J Clin Oncol. 2017 Dec;13(6):379-384. doi: 10.1111/ajco.12669. Epub 2017 Mar 8.

引用本文的文献

1
Novel kinase-activating genetic events in non-small cell lung carcinomas.非小细胞肺癌中的新型激酶激活基因事件。
Explor Target Antitumor Ther. 2025 Jul 9;6:1002330. doi: 10.37349/etat.2025.1002330. eCollection 2025.
2
Deciphering protective genomic factors of tumor development in pediatric Down syndrome via deep learning approach to whole genome and RNA sequencing.通过深度学习方法对全基因组和RNA测序来解读小儿唐氏综合征肿瘤发生的保护性基因组因素。
Cancer Commun (Lond). 2024 Nov;44(11):1374-1378. doi: 10.1002/cac2.12612. Epub 2024 Oct 10.
3
Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome.
35023 例中国实体瘤患者中 EGFR 融合的分布：频率、融合伙伴和临床结局。
World J Surg Oncol. 2024 Jul 25;22(1):194. doi: 10.1186/s12957-024-03463-w.
4
Global impact of somatic structural variation on the cancer proteome.体细胞结构变异对癌症蛋白质组的全球影响。
Nat Commun. 2023 Sep 13;14(1):5637. doi: 10.1038/s41467-023-41374-8.
5
A novel acquired fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma.一种新获得的融合基因赋予肺腺癌对表皮生长因子受体（EGFR）抑制剂不同的耐药性。
Genes Dis. 2023 Apr 24;10(6):2241-2244. doi: 10.1016/j.gendis.2023.02.019. eCollection 2023 Nov.
6
Profiling of gene fusion involving targetable genes in Chinese gastric cancer.中国胃癌中涉及可靶向基因的基因融合分析
World J Gastrointest Oncol. 2022 Aug 15;14(8):1528-1539. doi: 10.4251/wjgo.v14.i8.1528.
7
Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.在一名EGFR L858R肺腺癌患者中出现一种新型的VOPP1-EGFR融合基因与T790M共存，作为对先前埃克替尼的获得性耐药机制且对奥希替尼敏感：一例报告
Front Oncol. 2021 Dec 22;11:720819. doi: 10.3389/fonc.2021.720819. eCollection 2021.
8
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.受体酪氨酸激酶及其信号通路作为姜黄素在癌症治疗中的靶点
Front Pharmacol. 2021 Nov 15;12:772510. doi: 10.3389/fphar.2021.772510. eCollection 2021.
9
Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.吉非替尼联合西妥昔单抗治疗携带 EGFR 基因间区（SEC61G）融合和 EGFR 扩增的肺腺癌。
Oncologist. 2021 Nov;26(11):e1898-e1902. doi: 10.1002/onco.13921. Epub 2021 Aug 18.
10
A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report.非小细胞肺癌中的一种新型KIF5B-EGFR融合变体及其对阿法替尼的反应：病例报告
Onco Targets Ther. 2021 Jun 14;14:3739-3744. doi: 10.2147/OTT.S313896. eCollection 2021.